الفهرس 
• Introduction to HCVOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection worldwide, ranging from 6% to more than 40% and has rising rates for HCC development.
HCC is one of the most common and aggressive malignancies worldwide. It is the third most common cause of cancer related death worldwide.
Early detection of HCC greatly improve outcome and improve five year survival rate.
The most commonly used tools for diagnosis of HCC are ultrasonography and measurements of AFP in blood, While the serological AFP blood test is non-invasive, inexpensive and reproducible, screening programs that utilize the test suffer from limitations in this marker’s sensitivity and specificity. The poor sensitivity of AFP explains its absence from the American Association for the Study of Liver Disease (AASLD) practice Guidelines as a test recommended for screening of HCC. This substandard sensitivity underlines the need for a biomarker that is able to detect HCC at an early stage.
Soluble CD25 was identified previously as a marker for HCC.
This study was conducted to evaluate the level of s CD25 in HCC patients and HCV cirrhotic patients compared to normal healthy control group in order to evaluate the clinical effectiveness of s CD25 as a marker for early detection of HCC. The study was undertaken at Clinical Pathology Department and Gastroenterology and Hepatology Unit of Suez Canal University Hospital.